Next Article in Journal
Enhanced Therapeutic Effects of 177Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts
Next Article in Special Issue
A–Z of Epigenetic Readers: Targeting Alternative Splicing and Histone Modification Variants in Cancer
Previous Article in Journal
Polybrominated Diphenyl Ethers (PBDEs) and Human Health: Effects on Metabolism, Diabetes and Cancer
Previous Article in Special Issue
Acinic Cell Carcinoma in the 21st Century: A Population-Based Study from the SEER Database and Review of Recent Molecular Genetic Advances
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Genetics of ABCB1 in Cancer

by
Katie T. Skinner
1,2,
Antara M. Palkar
1,2 and
Andrew L. Hong
1,2,3,*
1
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
2
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA
3
Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(17), 4236; https://doi.org/10.3390/cancers15174236
Submission received: 14 July 2023 / Revised: 10 August 2023 / Accepted: 22 August 2023 / Published: 24 August 2023

Simple Summary

Overexpression of ABCB1 has been identified in a wide range of multidrug-resistant cancers. ABCB1 can become upregulated in many ways, and understanding these mechanisms of upregulation could provide novel insights into cancer multidrug resistance. In this review, we summarize genetic and epigenetic mechanisms of ABCB1 upregulation in cancer and highlight areas that may be relevant for future research.

Abstract

ABCB1, also known as MDR1, is a gene that encodes P-glycoprotein (P-gp), a membrane-associated ATP-dependent transporter. P-gp is widely expressed in many healthy tissues—in the gastrointestinal tract, liver, kidney, and at the blood–brain barrier. P-gp works to pump xenobiotics such as toxins and drugs out of cells. P-gp is also commonly upregulated across multiple cancer types such as ovarian, breast, and lung. Overexpression of ABCB1 has been linked to the development of chemotherapy resistance across these cancers. In vitro work across a wide range of drug-sensitive and -resistant cancer cell lines has shown that upon treatment with chemotherapeutic agents such as doxorubicin, cisplatin, and paclitaxel, ABCB1 is upregulated. This upregulation is caused in part by a variety of genetic and epigenetic mechanisms. This includes single-nucleotide variants that lead to enhanced P-gp ATPase activity without increasing ABCB1 RNA and protein levels. In this review, we summarize current knowledge of genetic and epigenetic mechanisms leading to ABCB1 upregulation and P-gp-enhanced ATPase activity in the setting of chemotherapy resistance across a variety of cancers.
Keywords: ABCB1; multidrug resistance; chemotherapy; genetics; epigenetics ABCB1; multidrug resistance; chemotherapy; genetics; epigenetics

Share and Cite

MDPI and ACS Style

Skinner, K.T.; Palkar, A.M.; Hong, A.L. Genetics of ABCB1 in Cancer. Cancers 2023, 15, 4236. https://doi.org/10.3390/cancers15174236

AMA Style

Skinner KT, Palkar AM, Hong AL. Genetics of ABCB1 in Cancer. Cancers. 2023; 15(17):4236. https://doi.org/10.3390/cancers15174236

Chicago/Turabian Style

Skinner, Katie T., Antara M. Palkar, and Andrew L. Hong. 2023. "Genetics of ABCB1 in Cancer" Cancers 15, no. 17: 4236. https://doi.org/10.3390/cancers15174236

APA Style

Skinner, K. T., Palkar, A. M., & Hong, A. L. (2023). Genetics of ABCB1 in Cancer. Cancers, 15(17), 4236. https://doi.org/10.3390/cancers15174236

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop